© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
Autoimmune Diseases
AGA Releases Expert Commentary for IBD Management During COVID-19
April 27, 2020
Depending on the situation, individuals with IBD who develop COVID-19 may want to alter their medication.
Long-Term Data Show Sustained Benefit of Siponimod for Secondary Progressive MS
April 22, 2020
Siponimod (Mayzent, Novartis) had a sustained effect on slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS), according to new long-term data from a phase 3 study.
FDA Accepts sBLA for Shorter Infusion Time with Ocrelizumab
April 20, 2020
Genentech is seeking approval for a 2-hour ocrelizumab (Ocrevus) infusion time in patients with relapsing or primary progressive multiple sclerosis.
Autoimmunity Prevalence Increasing in the United States
April 08, 2020
Autoimmunity and certain autoimmune diseases have been increasing in prevalence in the United States.
FDA OKs Ixekizumab for Pediatric Patients with Plaque Psoriasis
April 06, 2020
Officials with the FDA have granted approval to ixekizumab (Taltz, Eli Lilly) injection, 80 mg/mL for the treatment of pediatric patients with moderate-to-severe plaque psoriasis.
FDA Approves Ozanimod for Relapsing Multiple Sclerosis
March 27, 2020
Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.
What Pharmacists Should Know About Multiple Sclerosis
March 16, 2020
Approximately 1 million individuals are living with multiple sclerosis in the United States, according to the National MS Society.
What Pharmacists Should Know About Trends in IBD Treatment
February 10, 2020
Pharmacists can play an integral role in managing patients with inflammatory bowel disease (IBD) through medication management.
New Phase 3 Data on Baricitinib Efficacy in Atopic Dermatitis
February 04, 2020
Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.
AGA Releases New Guidelines on Management of Ulcerative Colitis
January 24, 2020
Evidence-based recommendations focus on immunomodulators, biologics, and small molecules for the management of ulcerative colitis.